GCC Clinical Trial Market Outlook 2025
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
'GCC Clinical Trial Market Outlook 2025' Report Highlights:
The growth observed in the GCC clinical trial market is filled with pool of opportunities and varying trends at the level of stakeholders and the researchers. Various obstacles that are observed while building the clinical research capacity in the region have been well adjusted as there are several different facilitators that have optimized the high ground cost of clinical research studies. GCC clinical trial market provides an advantageous landscape of conducting clinical research as it is holding epidemiological profile and ethnic diversity. In terms of technology, concentration of the fully advanced equipments have also observed an influx in the market. All this is estimated to be a contribution of economic development that has taken place in the region so far.
The clinical research credentials such as patient enrollment, infrastructure and equipped laboratories in every country in the gulf have fundamentally revolutionized the pattern of running larger clinical trials. Saudi Arabia & UAE among all the gulf countries have helped the region to set a phenomenon that has majorly impacted several emerging clinical trial markets of the world. Clinical trial landscape in the respective countries have undergone a transitional state and have eventually resulted in alarming the other emerged markets of the world about the upcoming dominant market. Currently, both the countries are holding hundreds of clinical trials for almost half of the major mortality causing diseases in the world.
Other than the population drive that is considered as an important key parameter for the future assembly of the GCC clinical trial market, the parameter that is expected to drive the future scenario of the market is the gradual increase in the geriatric population. It is estimated that by the end of year 2050, there will be more than 25 Million people aged 60 years and above. The analysis that has been made for the future percentage of geriatric population is driving the upcoming years of the GCC clinical trial market.
The future insights of the GCC clinical trial market is estimated to bring laurels to the overall pharmaceutical market. The initiatives taken up by the government of the respective countries in long run such as Vision 2030 by Saudi Arabia is also motivating the researchers to enforce various different strategies that could boost the future of the clinical trial market as well as the pharmaceutical market.
As per the research report, the current scenario of the GCC clinical trial market represents a phase where it is moving towards disrupting the established status of other emerged markets of the world. The market is approaching several different go-to-market strategies in order to enhance the experiences as well as the insights regarding the data-driven clinical studies. With the introduction of several different smart applications in the market, it is leading towards an augmented and impactful strike against the major position holders in the global market. Over the last few years, the market is inclining towards the diseases whose prevalence in the region is increasing furiously. It is estimated that in the near future, with the technologies to redefine the outlook, the market will hold the potential to thrive promisingly into the global market.
'GCC Clinical Trial Market Outlook 2025' Report Highlights:
- GCC Clinical Trial Market Opportunity: >US$ 500 Million
- GCC Disease Prevalence & Statistics
- Saudi Arabia Dominating GCC Clinical Trial Landscape: > 500 Trials
- Clinical Trials for Cancer in GCC: > 120 Trials
- Guidelines For Conducting Clinical Trials by Country
- Ongoing Clinical Trials Insight by Country
The growth observed in the GCC clinical trial market is filled with pool of opportunities and varying trends at the level of stakeholders and the researchers. Various obstacles that are observed while building the clinical research capacity in the region have been well adjusted as there are several different facilitators that have optimized the high ground cost of clinical research studies. GCC clinical trial market provides an advantageous landscape of conducting clinical research as it is holding epidemiological profile and ethnic diversity. In terms of technology, concentration of the fully advanced equipments have also observed an influx in the market. All this is estimated to be a contribution of economic development that has taken place in the region so far.
The clinical research credentials such as patient enrollment, infrastructure and equipped laboratories in every country in the gulf have fundamentally revolutionized the pattern of running larger clinical trials. Saudi Arabia & UAE among all the gulf countries have helped the region to set a phenomenon that has majorly impacted several emerging clinical trial markets of the world. Clinical trial landscape in the respective countries have undergone a transitional state and have eventually resulted in alarming the other emerged markets of the world about the upcoming dominant market. Currently, both the countries are holding hundreds of clinical trials for almost half of the major mortality causing diseases in the world.
Other than the population drive that is considered as an important key parameter for the future assembly of the GCC clinical trial market, the parameter that is expected to drive the future scenario of the market is the gradual increase in the geriatric population. It is estimated that by the end of year 2050, there will be more than 25 Million people aged 60 years and above. The analysis that has been made for the future percentage of geriatric population is driving the upcoming years of the GCC clinical trial market.
The future insights of the GCC clinical trial market is estimated to bring laurels to the overall pharmaceutical market. The initiatives taken up by the government of the respective countries in long run such as Vision 2030 by Saudi Arabia is also motivating the researchers to enforce various different strategies that could boost the future of the clinical trial market as well as the pharmaceutical market.
As per the research report, the current scenario of the GCC clinical trial market represents a phase where it is moving towards disrupting the established status of other emerged markets of the world. The market is approaching several different go-to-market strategies in order to enhance the experiences as well as the insights regarding the data-driven clinical studies. With the introduction of several different smart applications in the market, it is leading towards an augmented and impactful strike against the major position holders in the global market. Over the last few years, the market is inclining towards the diseases whose prevalence in the region is increasing furiously. It is estimated that in the near future, with the technologies to redefine the outlook, the market will hold the potential to thrive promisingly into the global market.
1. GCC CLINICAL MARKET REGIONAL INSIGHTS
2. GCC CLINICAL TRIAL MARKET DYNAMICS
2.1 Driving Forces for GCC Clinical Trial Market
2.2 Challenges for GCC Clinical Trial Market
3. GCC - REGULATORY ASPECTS OF PHARMACEUTICALS
3.1 Gulf Central Committee for Drug Registrations (GCC-DR)
3.2 Regulatory Review Process
3.3 Centralized Registration
3.4 Decentralized Drug Registration Regulation
3.4.1 Saudi Arabia
3.4.2 Kuwait
3.4.3 UAE
3.4.4 Bahrain
3.4.5 Qatar
3.4.6 Oman
3.5 Gulf Joint Procurement Program
4. GCC DISEASE PREVALENCE & STATISTICS
4.1 Cancer
4.1.1 Overview
4.1.2 Prevalence by Cancer Type & Gender
4.1.3 Cancer Prevalence & Statistics by GCC Countries
4.2 Diabetes
4.3 HIV/AIDS
4.4 Cardiovascular Diseases
4.4.1 Coronary Heart Disease
4.4.2 Hypertension
4.4.3 Stroke
4.5 Obesity
4.6 Respiratory Disorders
4.6.1 Asthma
4.6.2 Tuberculosis
4.6.3 Influenza & Pneumonia
4.6.4 Other Respiratory Diseases - COPD & Cystic Fibrosis
4.7 Alzheimer’s Disease/Dementia
5. SAUDI ARABIA - ONGOING CLINICAL TRIALS INSIGHT
5.1 Overview
5.2 By Indication
5.2.1 Cancer
5.2.2 Diabetes
5.2.3 Cardiovascular Diseases
5.2.4 Respiratory Diseases Excluding Lung Cancer
6. SAUDI ARABIA - GUIDELINES FOR CONDUCTING CLINICAL TRIALS
6.1 The Principles of SFDA Guidelines
6.2 Protection of Trial Subjects
6.3 Institutional Review Board (IRB) Committee
6.3.1 Responsibilities
6.3.2 Composition, Functions, and Operations
6.3.3 Procedures
6.3.4 Records
6.4 Investigators
6.4.1 Qualifications and Agreements
6.4.2 Adequate Resources & Medical Care of Trial Subjects
6.5 Clinical Trial Protocols
7. UAE - ONGOING CLINICAL TRIALS INSIGHT
7.1 Overview
7.2 By Indication
7.2.1 Cancer
7.2.2 Diabetes
7.2.3 CVS Disorders
8. UAE - GUIDELINES FOR CLINICAL TRIALS CONDUCTION
8.1 General Provisions For Clinical Trials
8.1.1 Purpose & Scope
8.1.2 Clinical Trials Background
8.2 Suitability Of Individuals AND Sites Involved In Conducting The Clinical Trial
8.3 Protection of Subjects & Informed Consent
8.3.1 Research Subjects
8.3.2 Information and Consent
8.4 Clinical Trials With Vulnerable Groups (Vulnerable Subjects) Of Patients
8.5 Ethics & Research Committees
8.6 Authorization to Conduct Clinical Trials & Application to Ethics Committee
8.7 Amendments & Suspensions In Clinical Trials
8.7.1 Amendments In Clinical Trials
8.7.2 Suspension Of The Clinical Trial
9. BAHRAIN - ONGOING CLINICAL TRIALS INSIGHT
9.1 Overview
9.2 By Indication
10. BAHRAIN - GUIDELINES FOR CLINICAL TRIALS APPLICATION
10.1 Introduction
10.2 The Application Process
10.3 Phase II &III Clinical Trials: Decision Process
10.4 Guidelines Phase IV Clinical Trials
10.4.1 Application Process
10.4.2 DECISION PROCESS
10.5 Amendments
11. OMAN - ONGOING CLINICAL TRIALS INSIGHT
11.1 Overview
11.2 By Indication
11.2.1 Sickle Cell Disease
11.2.2 Cancer
12. OMAN - GUIDELINES FOR CLINICAL TRIAL CONDUCTION
12.1 Provision & Prerequisites for a Clinical Trial
12.2 Protection of Clinical Trial Participants
12.2.1 Research and Ethics Committee
12.2.2 Informed Consent of Trial Participants
12.2.3 Privacy and Confidentiality
12.3 Documents and Requirements for Clinical Studies and Trials
12.3.1 Documents Required to be Submitted to Central RERAC for Approval of
Clinical Trials
12.3.2 Documents Required During the Clinical Conduct of the Trial
12.3.3 Other Documents which are Required During the Clinical Conduct of the
Trial
12.3.4 The Required Documents by the End of the Trial
13. KUWAIT - ONGOING CLINICAL TRIALS INSIGHT
13.1 Overview
13.2 By Indication
13.2.1 Cancer Related Trials
13.2.2 Diabetes Related Trial
14. QATAR - ONGOING CLINICAL TRIALS INSIGHT
14.1 Overview
14.2 By Indication
14.2.1 Cancer Related Trials
14.2.2 Diabetes Related Trial
14.2.3 CVS Disorders
14.2.4 Respiratory Disease
15. FUTURE INSIGHTS FOR GCC CLINICAL TRIAL MARKET
16. COMPETITIVE LANDSCAPE
16.1 Regional CROs
16.1.1 Innova
16.1.2 Antaea
16.1.3 ClinServ International
16.1.4 MCRO
16.1.5 KAU MED Clinical Research Organization
16.1.6 RAY CRO
16.1.7 MCT CRO
16.1.8 ClinArt MENA
16.1.9 Pharmaceutical Development Company
16.1.10 Nagy Research MEACRO
16.2 Multinational CROs
16.2.1 Quotient Sciences
16.2.2 MedPace
16.2.3 Europe, Middle East & Africa Clinical Research (EMEACR)
16.2.4 Pharmaceutical Product Development (PPD)
16.2.5 MedPace
16.2.6 PRA Health Sciences
16.2.7 KCR
16.2.8 ICON
16.2.9 Covance
16.2.10 Parexel
2. GCC CLINICAL TRIAL MARKET DYNAMICS
2.1 Driving Forces for GCC Clinical Trial Market
2.2 Challenges for GCC Clinical Trial Market
3. GCC - REGULATORY ASPECTS OF PHARMACEUTICALS
3.1 Gulf Central Committee for Drug Registrations (GCC-DR)
3.2 Regulatory Review Process
3.3 Centralized Registration
3.4 Decentralized Drug Registration Regulation
3.4.1 Saudi Arabia
3.4.2 Kuwait
3.4.3 UAE
3.4.4 Bahrain
3.4.5 Qatar
3.4.6 Oman
3.5 Gulf Joint Procurement Program
4. GCC DISEASE PREVALENCE & STATISTICS
4.1 Cancer
4.1.1 Overview
4.1.2 Prevalence by Cancer Type & Gender
4.1.3 Cancer Prevalence & Statistics by GCC Countries
4.2 Diabetes
4.3 HIV/AIDS
4.4 Cardiovascular Diseases
4.4.1 Coronary Heart Disease
4.4.2 Hypertension
4.4.3 Stroke
4.5 Obesity
4.6 Respiratory Disorders
4.6.1 Asthma
4.6.2 Tuberculosis
4.6.3 Influenza & Pneumonia
4.6.4 Other Respiratory Diseases - COPD & Cystic Fibrosis
4.7 Alzheimer’s Disease/Dementia
5. SAUDI ARABIA - ONGOING CLINICAL TRIALS INSIGHT
5.1 Overview
5.2 By Indication
5.2.1 Cancer
5.2.2 Diabetes
5.2.3 Cardiovascular Diseases
5.2.4 Respiratory Diseases Excluding Lung Cancer
6. SAUDI ARABIA - GUIDELINES FOR CONDUCTING CLINICAL TRIALS
6.1 The Principles of SFDA Guidelines
6.2 Protection of Trial Subjects
6.3 Institutional Review Board (IRB) Committee
6.3.1 Responsibilities
6.3.2 Composition, Functions, and Operations
6.3.3 Procedures
6.3.4 Records
6.4 Investigators
6.4.1 Qualifications and Agreements
6.4.2 Adequate Resources & Medical Care of Trial Subjects
6.5 Clinical Trial Protocols
7. UAE - ONGOING CLINICAL TRIALS INSIGHT
7.1 Overview
7.2 By Indication
7.2.1 Cancer
7.2.2 Diabetes
7.2.3 CVS Disorders
8. UAE - GUIDELINES FOR CLINICAL TRIALS CONDUCTION
8.1 General Provisions For Clinical Trials
8.1.1 Purpose & Scope
8.1.2 Clinical Trials Background
8.2 Suitability Of Individuals AND Sites Involved In Conducting The Clinical Trial
8.3 Protection of Subjects & Informed Consent
8.3.1 Research Subjects
8.3.2 Information and Consent
8.4 Clinical Trials With Vulnerable Groups (Vulnerable Subjects) Of Patients
8.5 Ethics & Research Committees
8.6 Authorization to Conduct Clinical Trials & Application to Ethics Committee
8.7 Amendments & Suspensions In Clinical Trials
8.7.1 Amendments In Clinical Trials
8.7.2 Suspension Of The Clinical Trial
9. BAHRAIN - ONGOING CLINICAL TRIALS INSIGHT
9.1 Overview
9.2 By Indication
10. BAHRAIN - GUIDELINES FOR CLINICAL TRIALS APPLICATION
10.1 Introduction
10.2 The Application Process
10.3 Phase II &III Clinical Trials: Decision Process
10.4 Guidelines Phase IV Clinical Trials
10.4.1 Application Process
10.4.2 DECISION PROCESS
10.5 Amendments
11. OMAN - ONGOING CLINICAL TRIALS INSIGHT
11.1 Overview
11.2 By Indication
11.2.1 Sickle Cell Disease
11.2.2 Cancer
12. OMAN - GUIDELINES FOR CLINICAL TRIAL CONDUCTION
12.1 Provision & Prerequisites for a Clinical Trial
12.2 Protection of Clinical Trial Participants
12.2.1 Research and Ethics Committee
12.2.2 Informed Consent of Trial Participants
12.2.3 Privacy and Confidentiality
12.3 Documents and Requirements for Clinical Studies and Trials
12.3.1 Documents Required to be Submitted to Central RERAC for Approval of
Clinical Trials
12.3.2 Documents Required During the Clinical Conduct of the Trial
12.3.3 Other Documents which are Required During the Clinical Conduct of the
Trial
12.3.4 The Required Documents by the End of the Trial
13. KUWAIT - ONGOING CLINICAL TRIALS INSIGHT
13.1 Overview
13.2 By Indication
13.2.1 Cancer Related Trials
13.2.2 Diabetes Related Trial
14. QATAR - ONGOING CLINICAL TRIALS INSIGHT
14.1 Overview
14.2 By Indication
14.2.1 Cancer Related Trials
14.2.2 Diabetes Related Trial
14.2.3 CVS Disorders
14.2.4 Respiratory Disease
15. FUTURE INSIGHTS FOR GCC CLINICAL TRIAL MARKET
16. COMPETITIVE LANDSCAPE
16.1 Regional CROs
16.1.1 Innova
16.1.2 Antaea
16.1.3 ClinServ International
16.1.4 MCRO
16.1.5 KAU MED Clinical Research Organization
16.1.6 RAY CRO
16.1.7 MCT CRO
16.1.8 ClinArt MENA
16.1.9 Pharmaceutical Development Company
16.1.10 Nagy Research MEACRO
16.2 Multinational CROs
16.2.1 Quotient Sciences
16.2.2 MedPace
16.2.3 Europe, Middle East & Africa Clinical Research (EMEACR)
16.2.4 Pharmaceutical Product Development (PPD)
16.2.5 MedPace
16.2.6 PRA Health Sciences
16.2.7 KCR
16.2.8 ICON
16.2.9 Covance
16.2.10 Parexel
LIST OF FIGURES
Figure 1-1: GCC - Clinical Trials Market Opportunity (US$ Million), 2020 -2025
Figure 1-2: GCC – Clinical Trials for Cancer Indication, 2020
Figure 1-3: GCC – Distribution of Clinical Trials for Different Indications
Figure 3-1: GCC - Types of Drug Registration Process
Figure 3-2: Process Map for GCC Centralized Registration
Figure 3-3: GCC – Innovative/Biological and Generic Drug Registration Fees for Evaluation Procedures (SAR/US$), 2020
Figure 3-4: GCC – Innovative/Biological and Generic Drug Registration Renewal Fees (SAR/US$), 2020
Figure 3-5: GCC – Registration Fees for Addition of New Pharmaceutical Form, New Strength & New Pack Size for Innovative/Biological Products (SAR/US$), 2020
Figure 3-6: GCC – Registration Fees for Addition of New Pharmaceutical Form, New Strength & New Pack Size for Generic Products (SAR/US$), 2020
Figure 3-7: GCC – Registration Fees for Addition of New Pharmaceutical Form, New Strength & New Pack Size for Intravenous Generic Products (SAR/US$), 2020
Figure 3-8: Saudi Arabia – Regulatory Process for Pharmaceuticals
Figure 3-9: Kuwait – Regulatory Process for Pharmaceuticals
Figure 3-10: UAE - Regulatory Process for Pharmaceuticals
Figure 3-11: Bahrain – Regulatory Process for Pharmaceuticals
Figure 3-12: Qatar – Regulatory Process for Pharmaceuticals
Figure 3-13: Oman – Regulatory Process for Pharmaceuticals
Figure 4-1: GCC – Number of Newly Diagnosed Cancer Cases & Deaths, 2018
Figure 4-2: GCC – Number of New Cancer Cases by Countries, 2018
Figure 4-3: GCC – New Cancer Cases by Countries (%), 2018
Figure 4-4: GCC – Number of Cancer Related Deaths by Countries, 2018
Figure 4-5: GCC – New Cancer Cases by Countries (%), 2018
Figure 4-6: GCC – Number of Newly Diagnosed Cancer Cases, 2018 & 2030
Figure 4-7: GCC – Age Standardized Cancer Incidence Rate by Countries (per 100,000 People), 2018
Figure 4-8: GCC – Age Standardized Cancer Mortality Rate by Countries (per 100,000 People), 2018
Figure 4-9: GCC Pharmaceutical Market Size – Total vs. Cancer Drugs (US$ Billion), 2018
Figure 4-10: GCC – Cancer Drug Market Size by Countries (%), 2018
Figure 4-11: GCC – Number of New Diagnosed Cases by Cancer Type, 2018
Figure 4-12: GCC – New Diagnosed Cases by Cancer Type (%), 2018
Figure 4-13: GCC – Number of Cancer Cases & Deaths by Gender, 2018
Figure 4-14: GCC – Cancer Cases by Gender (%), 2018
Figure 4-15: GCC – Cancer Deaths by Gender (%), 2018
Figure 4-16: GCC – Age Standardized Cancer Incidence & Mortality Rate (per 100,000 People), 2018
Figure 4-17: Saudi Arabia – Number of Cancer Cases & Deaths, 2018
Figure 4-18: Saudi Arabia – Number of Cancer Cases & Deaths by Gender, 2018
Figure 4-19: Saudi Arabia – New Diagnosed Cancer Cases by Gender (%), 2018
Figure 4-20: Saudi Arabia – Cancer Related Deaths by Gender (%), 2018
Figure 4-21: Saudi Arabia – New Diagnosed Cases by Cancer Type (%), 2018
Figure 4-22: UAE - Number of Cancer Cases & Deaths, 2018
Figure 4-23: UAE – Number of Cancer Cases & Deaths by Gender, 2018
Figure 4-24: UAE – New Diagnosed Cases by Cancer Type (%), 2018
Figure 4-25: UAE – Number of New Diagnosed Cases by Cancer Type, 2018
Figure 4-26: Kuwait - Number of Cancer Cases & Deaths, 2018
Figure 4-27: Kuwait – Number of Cancer Cases & Deaths by Gender, 2018
Figure 4-28: Kuwait – New Diagnosed Cases by Cancer Type (%), 2018
Figure 4-29: Kuwait – Number of New Diagnosed Cases by Cancer Type, 2018
Figure 4-30: Bahrain - Number of Cancer Cases & Deaths, 2018
Figure 4-31: Bahrain – Number of Cancer Cases & Deaths by Gender, 2018
Figure 4-32: Bahrain – New Diagnosed Cases by Cancer Type (%), 2018
Figure 4-33: Bahrain – Number of New Diagnosed Cases by Cancer Type, 2018
Figure 4-34: Qatar - Number of Cancer Cases & Deaths, 2018
Figure 4-35: Qatar – Number of Cancer Cases & Deaths by Gender, 2018
Figure 4-36: Qatar – New Diagnosed Cases by Cancer Type (%), 2018
Figure 4-37: Qatar – Number of New Diagnosed Cases by Cancer Type, 2018
Figure 4-38: Oman - Number of Cancer Cases & Deaths, 2018
Figure 4-39: Oman – Number of Cancer Cases & Deaths by Gender, 2018
Figure 4-40: Oman – New Diagnosed Cases by Cancer Type (%), 2018
Figure 4-41: Oman – Number of New Diagnosed Cases by Cancer Type, 2018
Figure 4-42: GCC – Total Adult Population & Diabetic Population (Million), 2017
Figure 4-43: GCC – Total Adult Population & Diabetic Population (%), 2017
Figure 4-44: GCC – Diabetic Population by Countries (Million), 2017
Figure 4-45: GCC – Diabetic Population by Countries (%), 2017
Figure 4-46: GCC – Diabetes Related Deaths by Countries, 2017
Figure 4-47: GCC – Diabetes Related Deaths by Countries (%), 2017
Figure 4-48: GCC – Diabetes Prevalence Rate by Countries (%), 2017
Figure 4-49: GCC – Age Standardized Diabetes Death Rate by Countries (Per 100,000 People), 2017
Figure 4-50: GCC – Diabetic Population (Billion), 2017, 2018 & 2045
Figure 4-51: Saudi Arabia – Total HIV Cases & Newly Diagnosed HIV Cases, 2017
Figure 4-52: Saudi Arabia – New Diagnosed HIV Cases, 2013 - 2017
Figure 4-53: Saudi Arabia – New Diagnosed HIV Cases by Gender, 2017
Figure 4-54: Saudi Arabia - New Diagnosed HIV Cases by Gender (%), 2017
Figure 4-55: Saudi Arabia – Total HIV Cases by Gender, 2017
Figure 4-56: Saudi Arabia – Total HIV Cases by Gender, 2017
Figure 4-57: Saudi Arabia – Cumulative HIV Related Deaths by Gender, 2017
Figure 4-58: Saudi Arabia – Cumulative Number of HIV Patients on Anti-retroviral Therapy, 2017
Figure 4-59: UAE – Cumulative Number of HIV Patients, 2012, 2014 & 2016
Figure 4-60: UAE – Number of New HIV Cases & Deaths, 2016
Figure 4-61: UAE – Cumulative Number of HIV Patients on Anti-retroviral Therapy, 2012, 2014 & 2018
Figure 4-62: UAE – Cumulative Number of HIV Patients, 2014 - 2018
Figure 4-63: Bahrain – HIV Associated New Cases & Deaths, 2016
Figure 4-64: Bahrain – Patients Receiving Antiretroviral Therapy (%), 2012, 2014 & 2016
Figure 4-65: Qatar – Cumulative Number of HIV Cases & Patients on Antiretroviral Therapy, 1984 - 2014
Figure 4-66: Qatar – HIV Patients on Anti-Retroviral Therapy, 1984 - 2014
Figure 4-67: Oman – Cumulative HIV Cases, 2014, 2016 & 2018
Figure 4-68: Oman – Cumulative HIV Cases by Gender, 2018
Figure 4-69: Oman – Cumulative HIV Cases by Gender (%), 2018
Figure 4-70: Oman – Cumulative HIV Cases by Age, 2018
Figure 4-71: GCC – Age Standardized Coronary Heart Disease Death Rate by Countries, 2017
Figure 4-72: GCC – CHD Related Deaths by Countries, 2017
Figure 4-73: GCC – CHD Related Deaths by Countries (%), 2017
Figure 4-74: GCC – Age Standardized Hypertension Death Rate by Countries, 2017
Figure 4-75: GCC – Hypertension Related Deaths by Countries, 2017
Figure 4-76: GCC – Hypertension Related Deaths by Countries (%), 2017
Figure 4-77: GCC – Age Standardized Stroke Death Rate by Countries, 2017
Figure 4-78: GCC – Stroke Related Deaths by Countries, 2017
Figure 4-79: GCC – Stroke Related Deaths by Countries (%), 2017
Figure 4-80: GCC – Obese Population by Countries (%), 2019
Figure 4-81: GCC – Body Mass Index by Countries, 2019
Figure 4-82: Saudi Arabia – Obesity Prevalence Rate (%), 2017 & 2022
Figure 4-83: Saudi Arabia – Obesity Prevalence Rate by Gender (%), 2017 & 2022
Figure 4-84: UAE – Prevalence Rate of Obesity & Overweight by Gender(%), 2016
Figure 4-85: UAE – Obese Adult Population (%), 2019
Figure 4-86: Kuwait – Prevalence Rate of Obesity & Overweight (%), 2016
Figure 4-87: Kuwait – Prevalence Rate of Obesity & Overweight by Gender (%), 2016
Figure 4-88: Bahrain – Prevalence Rate of Obesity & Overweight (%), 2016
Figure 4-89: Bahrain – Prevalence Rate of Obesity & Overweight by Gender (%), 2016
Figure 4-90: Qatar – Prevalence Rate of Obesity & Overweight (%), 2016
Figure 4-91: Qatar – Prevalence Rate of Obesity & Overweight by Gender (%), 2016
Figure 4-92: Oman – Obesity Prevalence Rate by Gender (%), 2016
Figure 4-93: GCC – Asthma Related Deaths by Countries, 2017
Figure 4-94: GCC – Asthma Related Deaths by Countries (%), 2017
Figure 4-95: GCC – Age Standardized Asthma Death Rate by Countries (per 100,000 People), 2017
Figure 4-96: GCC – Tuberculosis Related Deaths by Countries, 2017
Figure 4-97: GCC – Age Standardized Incidence Rate of Tuberculosis by Countries (Per 100,000 People), 2017
Figure 4-98: GCC – Asthma Related Deaths by Countries (%), 2017
Figure 4-99: GCC – Age Standardized Tuberculosis Death Rate by Countries (per 100,000 People), 2017
Figure 4-100: GCC – Influenza & Pneumonia Related Deaths by Countries, 2017
Figure 4-101: GCC – Influenza & Pneumonia Related Deaths by Countries (%), 2017
Figure 4-102: GCC – Age Standardized Influenza & Pneumonia Death Rate by Countries (per 100,000 People), 2017
Figure 4-103: GCC – COPD Prevalence Rate by Countries (%), 2018
Figure 4-104: GCC – COPD & Cystic Fibrosis Related Deaths by Countries, 2017
Figure 4-105: GCC – COPD & Cystic Fibrosis Related Deaths by Countries (%), 2017
Figure 4-106: GCC – Age Standardized COPD & Cystic Fibrosis Death Rate by Countries (per 100,000 People), 2017
Figure 4-107: GCC – Alzheimer/Dementia Related Deaths by Countries, 2017
Figure 4-108: GCC – Alzheimer/Dementia Related Deaths by Countries (%), 2017
Figure 4-109: GCC – Age Standardized Alzheimer/Dementia Death Rate by Countries (per 100,000 People), 2017
Figure 5-1: Saudi Arabia – Number of Clinical Trials by Development Phase, 2020
Figure 5-2: Saudi Arabia – Clinical Trials by Development Phase (%), 2020
Figure 5-3: Saudi Arabia – Number of Clinical Trials by Status, 2020
Figure 5-4: Saudi Arabia – Number of Drugs in Clinical Trials by Development Phase, 2020
Figure 5-5: Saudi Arabia – Drugs in Clinical Trials by Development Phase (%), 2020
Figure 5-6: Saudi Arabia – Number of Drugs in Clinical Trials by Top 20 Indication, 2020
Figure 5-7: Saudi Arabia – Number of Drugs in Clinical Trials by Top 15 Drug Class, 2020
Figure 5-8: Saudi Arabia – Number of Drugs in Clinical Trials by Mechanism of Action, 2020
Figure 5-9: Saudi Arabia – Numbers of Clinical Trials by Indications, 2020
Figure 5-10: Saudi Arabia – Clinical Trials by Indications (%), 2020
Figure 5-11: Saudi Arabia – Number of Cancer Clinical Trials by Development Phase, 2020
Figure 5-12: Saudi Arabia – Cancer Clinical Trials by Development Phase (%), 2020
Figure 5-13: Saudi Arabia – Number of Cancer Clinical Trials by Status, 2020
Figure 5-14: Saudi Arabia – Cancer Clinical Trials by Status (%), 2020
Figure 5-15: Saudi Arabia – Number of Clinical Trials by Cancer Type, 2020
Figure 5-16: Saudi Arabia – Clinical Trials by Cancer Type (%), 2020
Figure 5-17: Saudi Arabia – Number of Breast Cancer Clinical Trials by Development Phase, 2020
Figure 5-18: Saudi Arabia – Breast Cancer Clinical Trials by Development Phase (%), 2020
Figure 5-19: Saudi Arabia – Number of Breast Cancer Clinical Trials by Status, 2020
Figure 5-20: Saudi Arabia – Number of Lung Cancer Clinical Trials by Development Phase, 2020
Figure 5-21: Saudi Arabia – Lung Cancer Clinical Trials by Development Phase (%), 2020
Figure 5-22: Saudi Arabia – Number of Lung Cancer Clinical Trials by Status, 2020
Figure 5-23: Saudi Arabia – Number of Leukemia Clinical Trials by Development Phase, 2020
Figure 5-24: Saudi Arabia – Leukemia Clinical Trials by Development Phase (%), 2020
Figure 5-25: Saudi Arabia – Number of Leukemia Clinical Trials by Status, 2020
Figure 5-26: Saudi Arabia – Number of Lymphoma Clinical Trials by Development Phase, 2020
Figure 5-27: Saudi Arabia – Lymphoma Clinical Trials by Development Phase (%), 2020
Figure 5-28: Saudi Arabia – Number of Lymphoma Clinical Trials by Status, 2020
Figure 5-29: Saudi Arabia – Total Clinical Trials v/s Diabetes Clinical Trial 2020
Figure 5-30: Saudi Arabia – Diabetes Clinical Trial by Type, 2020
Figure 5-31: Saudi Arabia – Diabetes Clinical Trial by Type, 2020
Figure 5-32: Saudi Arabia – Number of Diabetes Related Clinical Trials by Development Phase, 2020
Figure 5-33: Saudi Arabia – Number of Diabetes Related Clinical Trials by Development Phase, 2020
Figure 5-34: Saudi Arabia – Number of Clinical Trials by Status, 2020
Figure 5-35: Saudi Arabia – Total Clinical Trials v/s CVS Related Clinical Trial 2020
Figure 5-36: Saudi Arabia – CVS Clinical Trial by Type of Disease, 2020
Figure 5-37: Saudi Arabia – CVS Clinical Trial by Disease Type (%), 2020
Figure 5-38: Saudi Arabia – Number of CVS Related Clinical Trials by Development Phase, 2020
Figure 5-39: Saudi Arabia – Number of CVS Related Clinical Trials by Development Phase, 2020
Figure 5-40: Saudi Arabia – Number of CVS Related Clinical Trials by Status, 2020
Figure 5-41: Saudi Arabia – Total Clinical Trials v/s Respiratory Diseases (Excluding Lung Cancer) Clinical Trials, 2020
Figure 5-42: Saudi Arabia – Number of Respiratory Diseases (Excluding Lung Cancer) Related Clinical Trials by Development Phase, 2020
Figure 5-43: Saudi Arabia – Number of Respiratory Diseases (Excluding Lung Cancer) Related Clinical Trials by Development Phase, 2020
Figure 5-44: Saudi Arabia – Number of Respiratory Diseases (Excluding Lung Cancer) Related Clinical Trials by Status, 2020
Figure 7-1: UAE – Number of Clinical Trials by Development Phase, 2020
Figure 7-2: UAE – Clinical Trials by Development Phase (%), 2020
Figure 7-3: UAE – Number of Clinical Trials by Status, 2020
Figure 7-4: UAE – Number of Drugs in Clinical Trials by Development Phase, 2020
Figure 7-5: UAE – Drugs in Clinical Trials by Development Phase (%), 2020
Figure 7-6: UAE – Number of Drugs in Clinical Trials by Top 20 Indication, 2020
Figure 7-7: UAE – Number of Drugs in Clinical Trials by Top 15 Drug Class, 2020
Figure 7-8: UAE – Number of Drugs in Clinical Trials by Mechanism of Action, 2020
Figure 7-9: UAE – Numbers of Clinical Trials by Indications, 2020
Figure 7-10: UAE – Clinical Trials by Indications (%), 2020
Figure 7-11: UAE – Number of Cancer Clinical Trials by Development Phase, 2020
Figure 7-12: UAE – Cancer Clinical Trials by Development Phase (%), 2020
Figure 7-13: UAE – Number of Cancer Clinical Trials by Status, 2020
Figure 7-14: UAE – Cancer Clinical Trials by Status (%), 2020
Figure 7-15: UAE – Number of Clinical Trials by Cancer Type, 2020
Figure 7-16: UAE – Clinical Trials by Cancer Type (%), 2020
Figure 7-17: UAE – Number of Breast Cancer Clinical Trials by Development Phase, 2020
Figure 7-18: UAE – Breast Cancer Clinical Trials by Developmental Stage (%), 2020
Figure 7-19: UAE – Number of Breast Cancer Clinical Trials by Status, 2020
Figure 7-20: UAE – Number of Breast Cancer Clinical Trials by Development Phase, 2020
Figure 7-21: UAE – Breast Cancer Clinical Trials by Developmental Stage (%), 2020
Figure 7-22: UAE – Number of Breast Cancer Clinical Trials by Status, 2020
Figure 7-23: UAE – Total Clinical Trials v/s Diabetes Clinical Trial 2020
Figure 7-24: UAE – Diabetes Clinical Trial by Type, 2020
Figure 7-25: UAE – Diabetes Clinical Trial by Type, 2020
Figure 7-26: UAE – Number of Diabetes Related Clinical Trials by Development Phase, 2020
Figure 7-27: UAE – Number of Diabetes Related Clinical Trials by Development Phase, 2020
Figure 7-28: UAE – Number of Clinical Trials by Status, 2020
Figure 7-29: UAE – Total Clinical Trials v/s CVS Related Clinical Trial 2020
Figure 7-30: UAE – CVS Clinical Trial by Type of Disease, 2020
Figure 7-31: UAE – CVS Clinical Trial by Disease Type (%), 2020
Figure 7-32: UAE – Number of CVS Related Clinical Trials by Development Phase, 2020
Figure 7-33: UAE – Number of CVS Related Clinical Trials by Development Phase, 2020
Figure 7-34: UAE – Number of CVS Related Clinical Trials by Status, 2020
Figure 9-1: Bahrain – Number of Clinical Trials by Development Phase, 2020
Figure 9-2: Bahrain – Clinical Trials by Development Phase (%), 2020
Figure 9-3: Bahrain – Number of Clinical Trials by Status, 2020
Figure 9-4: Bahrain – Number of Drugs in Clinical Trials by Development Phase, 2020
Figure 9-5: Bahrain – Drugs in Clinical Trials by Development Phase (%), 2020
Figure 9-6: Bahrain – Number of Drugs in Clinical Trials by Top 20 Indication, 2020
Figure 9-7: Bahrain – Number of Drugs in Clinical Trials by Top 15 Drug Class, 2020
Figure 9-8: Bahrain – Number of Drugs in Clinical Trials by Mechanism of Action, 2020
Figure 9-9: Bahrain – Numbers of Clinical Trials by Indications, 2020
Figure 9-10: Bahrain – Clinical Trials by Indications (%), 2020
Figure 9-11: Bahrain – Number of COVID 19 Clinical Trials by Development Phase, 2020
Figure 9-12: Bahrain – COVID 19 Clinical Trials by Development Phase (%), 2020
Figure 9-13: Bahrain – Number of Clinical Trials by Status, 2020
Figure 11-1: Oman – Number of Clinical Trials by Development Phase, 2020
Figure 11-2: Oman – Clinical Trials by Development Phase (%), 2020
Figure 11-3: Oman – Number of Clinical Trials by Status, 2020
Figure 11-4: Oman – Number of Drugs in Clinical Trials by Development Phase, 2020
Figure 11-5: Oman – Drugs in Clinical Trials by Development Phase (%), 2020
Figure 11-6: Oman – Number of Drugs in Clinical Trials by Top 20 Indication, 2020
Figure 11-7: Oman – Number of Drugs in Clinical Trials by Top 15 Drug Class, 2020
Figure 11-8: Oman – Number of Drugs in Clinical Trials by Mechanism of Action, 2020
Figure 11-9: Oman – Numbers of Clinical Trials by Indications, 2020
Figure 11-10: Oman – Clinical Trials by Indications (%), 2020
Figure 11-11: Oman – Number of Sickle Cell Disease Clinical Trials by Development Phase, 2020
Figure 11-12: Oman – Sickle Cell Disease Clinical Trials by Development Phase (%), 2020
Figure 11-13: Oman – Number of Sickle Cell Disease Clinical Trials by Status, 2020
Figure 11-14: Oman – Number of Cancer Clinical Trials by Status, 2020
Figure 11-15: Oman – Cancer Clinical Trials by Status (%), 2020
Figure 11-16: Oman – Number of Clinical Trials by Type of Cancer, 2020
Figure 11-17: Oman – Clinical Trials by Type of Cancer (%), 2020
Figure 13-1: Kuwait – Number of Clinical Trials by Development Phase, 2020
Figure 13-2: Kuwait – Clinical Trials by Development Phase (%), 2020
Figure 13-3: Kuwait – Number of Clinical Trials by Status, 2020
Figure 13-4: Kuwait – Number of Drugs in Clinical Trials by Development Phase, 2020
Figure 13-5: Kuwait – Drugs in Clinical Trials by Development Phase (%), 2020
Figure 13-6: Kuwait – Number of Drugs in Clinical Trials by Top 20 Indication, 2020
Figure 13-7: Kuwait – Number of Drugs in Clinical Trials by Top 15 Drug Class, 2020
Figure 13-8: Kuwait – Number of Drugs in Clinical Trials by Mechanism of Action, 2020
Figure 13-9: Kuwait – Numbers of Clinical Trials by Indications, 2020
Figure 13-10: Kuwait – Clinical Trials by Indications (%), 2020
Figure 13-11: Kuwait – Number of Cancer Clinical Trials by Development Phase, 2020
Figure 13-12: Kuwait – Cancer Clinical Trials by Development Phase (%), 2020
Figure 13-13: Kuwait – Number of Cancer Clinical Trials by Status, 2020
Figure 13-14: Kuwait – Number of Clinical Trials by Type of Cancer, 2020
Figure 13-15: Kuwait – Total Clinical Trials v/s Diabetes Clinical Trial 2020
Figure 13-16: Kuwait – Diabetes Clinical Trial by Type, 2020
Figure 13-17: Kuwait – Diabetes Clinical Trial by Type, 2020
Figure 13-18: Kuwait – Number of Diabetes Related Clinical Trials by Development Phase, 2020
Figure 13-19: Kuwait – Number of Diabetes Related Clinical Trials by Development Phase, 2020
Figure 13-20: Kuwait – Number of Clinical Trials by Status, 2020
Figure 14-1: Qatar – Number of Clinical Trials by Development Phase, 2020
Figure 14-2: Qatar – Clinical Trials by Development Phase (%), 2020
Figure 14-3: Qatar – Number of Clinical Trials by Status, 2020
Figure 14-4: Qatar – Number of Drugs in Clinical Trials by Development Phase, 2020
Figure 14-5: Qatar – Drugs in Clinical Trials by Development Phase (%), 2020
Figure 14-6: Qatar – Number of Drugs in Clinical Trials by Top 20 Indication, 2020
Figure 14-7: Qatar – Number of Drugs in Clinical Trials by Top 15 Drug Class, 2020
Figure 14-8: Qatar – Number of Drugs in Clinical Trials by Top Mechanism of Action, 2020
Figure 14-9: Qatar – Numbers of Clinical Trials by Indications, 2020
Figure 14-10: Qatar – Clinical Trials by Indications (%), 2020
Figure 14-11: Qatar – Number of Cancer Clinical Trials by Development Phase, 2020
Figure 14-12: Qatar – Cancer Clinical Trials by Development Phase (%), 2020
Figure 14-13: Qatar – Number of Cancer Clinical Trials by Status, 2020
Figure 14-14: Qatar – Number of Clinical Trials by Type of Cancer, 2020
Figure 14-15: Qatar – Total Clinical Trials v/s Diabetes Clinical Trial 2020
Figure 14-16: Qatar – Diabetes Clinical Trial by Type, 2020
Figure 14-17: Qatar – Diabetes Clinical Trial by Type, 2020
Figure 14-18: Qatar – Number of Diabetes Related Clinical Trials by Development Phase, 2020
Figure 14-19: Qatar – Number of Diabetes Related Clinical Trials by Development Phase, 2020
Figure 14-20: Qatar – Number of Clinical Trials by Status, 2020
Figure 14-21: Qatar – Total Clinical Trials v/s CVS Related Clinical Trial 2020
Figure 14-22: Qatar – CVS Clinical Trial by Type of Disease, 2020
Figure 14-23: Qatar – Number of CVS Related Clinical Trials by Development Phase, 2020
Figure 14-24: Qatar – Number of CVS Related Clinical Trials by Development Phase, 2020
Figure 14-25: Qatar – Number of CVS Related Clinical Trials by Status, 2020
Figure 14-26: Qatar – Total Clinical Trials v/s Respiratory Disease (Except Lung Cancer) Related Clinical Trial 2020
Figure 14-27: Qatar – Number of Respiratory Diseases (Excluding Lung Cancer) Related Clinical Trials by Development Phase, 2020
Figure 14-28: Qatar – Number of Respiratory Diseases (Excluding Lung Cancer) Related Clinical Trials by Development Phase, 2020
Figure 14-29: Qatar – Number of Respiratory Diseases (Excluding Lung Cancer) Related Clinical Trials by Status, 2020
Figure 1-1: GCC - Clinical Trials Market Opportunity (US$ Million), 2020 -2025
Figure 1-2: GCC – Clinical Trials for Cancer Indication, 2020
Figure 1-3: GCC – Distribution of Clinical Trials for Different Indications
Figure 3-1: GCC - Types of Drug Registration Process
Figure 3-2: Process Map for GCC Centralized Registration
Figure 3-3: GCC – Innovative/Biological and Generic Drug Registration Fees for Evaluation Procedures (SAR/US$), 2020
Figure 3-4: GCC – Innovative/Biological and Generic Drug Registration Renewal Fees (SAR/US$), 2020
Figure 3-5: GCC – Registration Fees for Addition of New Pharmaceutical Form, New Strength & New Pack Size for Innovative/Biological Products (SAR/US$), 2020
Figure 3-6: GCC – Registration Fees for Addition of New Pharmaceutical Form, New Strength & New Pack Size for Generic Products (SAR/US$), 2020
Figure 3-7: GCC – Registration Fees for Addition of New Pharmaceutical Form, New Strength & New Pack Size for Intravenous Generic Products (SAR/US$), 2020
Figure 3-8: Saudi Arabia – Regulatory Process for Pharmaceuticals
Figure 3-9: Kuwait – Regulatory Process for Pharmaceuticals
Figure 3-10: UAE - Regulatory Process for Pharmaceuticals
Figure 3-11: Bahrain – Regulatory Process for Pharmaceuticals
Figure 3-12: Qatar – Regulatory Process for Pharmaceuticals
Figure 3-13: Oman – Regulatory Process for Pharmaceuticals
Figure 4-1: GCC – Number of Newly Diagnosed Cancer Cases & Deaths, 2018
Figure 4-2: GCC – Number of New Cancer Cases by Countries, 2018
Figure 4-3: GCC – New Cancer Cases by Countries (%), 2018
Figure 4-4: GCC – Number of Cancer Related Deaths by Countries, 2018
Figure 4-5: GCC – New Cancer Cases by Countries (%), 2018
Figure 4-6: GCC – Number of Newly Diagnosed Cancer Cases, 2018 & 2030
Figure 4-7: GCC – Age Standardized Cancer Incidence Rate by Countries (per 100,000 People), 2018
Figure 4-8: GCC – Age Standardized Cancer Mortality Rate by Countries (per 100,000 People), 2018
Figure 4-9: GCC Pharmaceutical Market Size – Total vs. Cancer Drugs (US$ Billion), 2018
Figure 4-10: GCC – Cancer Drug Market Size by Countries (%), 2018
Figure 4-11: GCC – Number of New Diagnosed Cases by Cancer Type, 2018
Figure 4-12: GCC – New Diagnosed Cases by Cancer Type (%), 2018
Figure 4-13: GCC – Number of Cancer Cases & Deaths by Gender, 2018
Figure 4-14: GCC – Cancer Cases by Gender (%), 2018
Figure 4-15: GCC – Cancer Deaths by Gender (%), 2018
Figure 4-16: GCC – Age Standardized Cancer Incidence & Mortality Rate (per 100,000 People), 2018
Figure 4-17: Saudi Arabia – Number of Cancer Cases & Deaths, 2018
Figure 4-18: Saudi Arabia – Number of Cancer Cases & Deaths by Gender, 2018
Figure 4-19: Saudi Arabia – New Diagnosed Cancer Cases by Gender (%), 2018
Figure 4-20: Saudi Arabia – Cancer Related Deaths by Gender (%), 2018
Figure 4-21: Saudi Arabia – New Diagnosed Cases by Cancer Type (%), 2018
Figure 4-22: UAE - Number of Cancer Cases & Deaths, 2018
Figure 4-23: UAE – Number of Cancer Cases & Deaths by Gender, 2018
Figure 4-24: UAE – New Diagnosed Cases by Cancer Type (%), 2018
Figure 4-25: UAE – Number of New Diagnosed Cases by Cancer Type, 2018
Figure 4-26: Kuwait - Number of Cancer Cases & Deaths, 2018
Figure 4-27: Kuwait – Number of Cancer Cases & Deaths by Gender, 2018
Figure 4-28: Kuwait – New Diagnosed Cases by Cancer Type (%), 2018
Figure 4-29: Kuwait – Number of New Diagnosed Cases by Cancer Type, 2018
Figure 4-30: Bahrain - Number of Cancer Cases & Deaths, 2018
Figure 4-31: Bahrain – Number of Cancer Cases & Deaths by Gender, 2018
Figure 4-32: Bahrain – New Diagnosed Cases by Cancer Type (%), 2018
Figure 4-33: Bahrain – Number of New Diagnosed Cases by Cancer Type, 2018
Figure 4-34: Qatar - Number of Cancer Cases & Deaths, 2018
Figure 4-35: Qatar – Number of Cancer Cases & Deaths by Gender, 2018
Figure 4-36: Qatar – New Diagnosed Cases by Cancer Type (%), 2018
Figure 4-37: Qatar – Number of New Diagnosed Cases by Cancer Type, 2018
Figure 4-38: Oman - Number of Cancer Cases & Deaths, 2018
Figure 4-39: Oman – Number of Cancer Cases & Deaths by Gender, 2018
Figure 4-40: Oman – New Diagnosed Cases by Cancer Type (%), 2018
Figure 4-41: Oman – Number of New Diagnosed Cases by Cancer Type, 2018
Figure 4-42: GCC – Total Adult Population & Diabetic Population (Million), 2017
Figure 4-43: GCC – Total Adult Population & Diabetic Population (%), 2017
Figure 4-44: GCC – Diabetic Population by Countries (Million), 2017
Figure 4-45: GCC – Diabetic Population by Countries (%), 2017
Figure 4-46: GCC – Diabetes Related Deaths by Countries, 2017
Figure 4-47: GCC – Diabetes Related Deaths by Countries (%), 2017
Figure 4-48: GCC – Diabetes Prevalence Rate by Countries (%), 2017
Figure 4-49: GCC – Age Standardized Diabetes Death Rate by Countries (Per 100,000 People), 2017
Figure 4-50: GCC – Diabetic Population (Billion), 2017, 2018 & 2045
Figure 4-51: Saudi Arabia – Total HIV Cases & Newly Diagnosed HIV Cases, 2017
Figure 4-52: Saudi Arabia – New Diagnosed HIV Cases, 2013 - 2017
Figure 4-53: Saudi Arabia – New Diagnosed HIV Cases by Gender, 2017
Figure 4-54: Saudi Arabia - New Diagnosed HIV Cases by Gender (%), 2017
Figure 4-55: Saudi Arabia – Total HIV Cases by Gender, 2017
Figure 4-56: Saudi Arabia – Total HIV Cases by Gender, 2017
Figure 4-57: Saudi Arabia – Cumulative HIV Related Deaths by Gender, 2017
Figure 4-58: Saudi Arabia – Cumulative Number of HIV Patients on Anti-retroviral Therapy, 2017
Figure 4-59: UAE – Cumulative Number of HIV Patients, 2012, 2014 & 2016
Figure 4-60: UAE – Number of New HIV Cases & Deaths, 2016
Figure 4-61: UAE – Cumulative Number of HIV Patients on Anti-retroviral Therapy, 2012, 2014 & 2018
Figure 4-62: UAE – Cumulative Number of HIV Patients, 2014 - 2018
Figure 4-63: Bahrain – HIV Associated New Cases & Deaths, 2016
Figure 4-64: Bahrain – Patients Receiving Antiretroviral Therapy (%), 2012, 2014 & 2016
Figure 4-65: Qatar – Cumulative Number of HIV Cases & Patients on Antiretroviral Therapy, 1984 - 2014
Figure 4-66: Qatar – HIV Patients on Anti-Retroviral Therapy, 1984 - 2014
Figure 4-67: Oman – Cumulative HIV Cases, 2014, 2016 & 2018
Figure 4-68: Oman – Cumulative HIV Cases by Gender, 2018
Figure 4-69: Oman – Cumulative HIV Cases by Gender (%), 2018
Figure 4-70: Oman – Cumulative HIV Cases by Age, 2018
Figure 4-71: GCC – Age Standardized Coronary Heart Disease Death Rate by Countries, 2017
Figure 4-72: GCC – CHD Related Deaths by Countries, 2017
Figure 4-73: GCC – CHD Related Deaths by Countries (%), 2017
Figure 4-74: GCC – Age Standardized Hypertension Death Rate by Countries, 2017
Figure 4-75: GCC – Hypertension Related Deaths by Countries, 2017
Figure 4-76: GCC – Hypertension Related Deaths by Countries (%), 2017
Figure 4-77: GCC – Age Standardized Stroke Death Rate by Countries, 2017
Figure 4-78: GCC – Stroke Related Deaths by Countries, 2017
Figure 4-79: GCC – Stroke Related Deaths by Countries (%), 2017
Figure 4-80: GCC – Obese Population by Countries (%), 2019
Figure 4-81: GCC – Body Mass Index by Countries, 2019
Figure 4-82: Saudi Arabia – Obesity Prevalence Rate (%), 2017 & 2022
Figure 4-83: Saudi Arabia – Obesity Prevalence Rate by Gender (%), 2017 & 2022
Figure 4-84: UAE – Prevalence Rate of Obesity & Overweight by Gender(%), 2016
Figure 4-85: UAE – Obese Adult Population (%), 2019
Figure 4-86: Kuwait – Prevalence Rate of Obesity & Overweight (%), 2016
Figure 4-87: Kuwait – Prevalence Rate of Obesity & Overweight by Gender (%), 2016
Figure 4-88: Bahrain – Prevalence Rate of Obesity & Overweight (%), 2016
Figure 4-89: Bahrain – Prevalence Rate of Obesity & Overweight by Gender (%), 2016
Figure 4-90: Qatar – Prevalence Rate of Obesity & Overweight (%), 2016
Figure 4-91: Qatar – Prevalence Rate of Obesity & Overweight by Gender (%), 2016
Figure 4-92: Oman – Obesity Prevalence Rate by Gender (%), 2016
Figure 4-93: GCC – Asthma Related Deaths by Countries, 2017
Figure 4-94: GCC – Asthma Related Deaths by Countries (%), 2017
Figure 4-95: GCC – Age Standardized Asthma Death Rate by Countries (per 100,000 People), 2017
Figure 4-96: GCC – Tuberculosis Related Deaths by Countries, 2017
Figure 4-97: GCC – Age Standardized Incidence Rate of Tuberculosis by Countries (Per 100,000 People), 2017
Figure 4-98: GCC – Asthma Related Deaths by Countries (%), 2017
Figure 4-99: GCC – Age Standardized Tuberculosis Death Rate by Countries (per 100,000 People), 2017
Figure 4-100: GCC – Influenza & Pneumonia Related Deaths by Countries, 2017
Figure 4-101: GCC – Influenza & Pneumonia Related Deaths by Countries (%), 2017
Figure 4-102: GCC – Age Standardized Influenza & Pneumonia Death Rate by Countries (per 100,000 People), 2017
Figure 4-103: GCC – COPD Prevalence Rate by Countries (%), 2018
Figure 4-104: GCC – COPD & Cystic Fibrosis Related Deaths by Countries, 2017
Figure 4-105: GCC – COPD & Cystic Fibrosis Related Deaths by Countries (%), 2017
Figure 4-106: GCC – Age Standardized COPD & Cystic Fibrosis Death Rate by Countries (per 100,000 People), 2017
Figure 4-107: GCC – Alzheimer/Dementia Related Deaths by Countries, 2017
Figure 4-108: GCC – Alzheimer/Dementia Related Deaths by Countries (%), 2017
Figure 4-109: GCC – Age Standardized Alzheimer/Dementia Death Rate by Countries (per 100,000 People), 2017
Figure 5-1: Saudi Arabia – Number of Clinical Trials by Development Phase, 2020
Figure 5-2: Saudi Arabia – Clinical Trials by Development Phase (%), 2020
Figure 5-3: Saudi Arabia – Number of Clinical Trials by Status, 2020
Figure 5-4: Saudi Arabia – Number of Drugs in Clinical Trials by Development Phase, 2020
Figure 5-5: Saudi Arabia – Drugs in Clinical Trials by Development Phase (%), 2020
Figure 5-6: Saudi Arabia – Number of Drugs in Clinical Trials by Top 20 Indication, 2020
Figure 5-7: Saudi Arabia – Number of Drugs in Clinical Trials by Top 15 Drug Class, 2020
Figure 5-8: Saudi Arabia – Number of Drugs in Clinical Trials by Mechanism of Action, 2020
Figure 5-9: Saudi Arabia – Numbers of Clinical Trials by Indications, 2020
Figure 5-10: Saudi Arabia – Clinical Trials by Indications (%), 2020
Figure 5-11: Saudi Arabia – Number of Cancer Clinical Trials by Development Phase, 2020
Figure 5-12: Saudi Arabia – Cancer Clinical Trials by Development Phase (%), 2020
Figure 5-13: Saudi Arabia – Number of Cancer Clinical Trials by Status, 2020
Figure 5-14: Saudi Arabia – Cancer Clinical Trials by Status (%), 2020
Figure 5-15: Saudi Arabia – Number of Clinical Trials by Cancer Type, 2020
Figure 5-16: Saudi Arabia – Clinical Trials by Cancer Type (%), 2020
Figure 5-17: Saudi Arabia – Number of Breast Cancer Clinical Trials by Development Phase, 2020
Figure 5-18: Saudi Arabia – Breast Cancer Clinical Trials by Development Phase (%), 2020
Figure 5-19: Saudi Arabia – Number of Breast Cancer Clinical Trials by Status, 2020
Figure 5-20: Saudi Arabia – Number of Lung Cancer Clinical Trials by Development Phase, 2020
Figure 5-21: Saudi Arabia – Lung Cancer Clinical Trials by Development Phase (%), 2020
Figure 5-22: Saudi Arabia – Number of Lung Cancer Clinical Trials by Status, 2020
Figure 5-23: Saudi Arabia – Number of Leukemia Clinical Trials by Development Phase, 2020
Figure 5-24: Saudi Arabia – Leukemia Clinical Trials by Development Phase (%), 2020
Figure 5-25: Saudi Arabia – Number of Leukemia Clinical Trials by Status, 2020
Figure 5-26: Saudi Arabia – Number of Lymphoma Clinical Trials by Development Phase, 2020
Figure 5-27: Saudi Arabia – Lymphoma Clinical Trials by Development Phase (%), 2020
Figure 5-28: Saudi Arabia – Number of Lymphoma Clinical Trials by Status, 2020
Figure 5-29: Saudi Arabia – Total Clinical Trials v/s Diabetes Clinical Trial 2020
Figure 5-30: Saudi Arabia – Diabetes Clinical Trial by Type, 2020
Figure 5-31: Saudi Arabia – Diabetes Clinical Trial by Type, 2020
Figure 5-32: Saudi Arabia – Number of Diabetes Related Clinical Trials by Development Phase, 2020
Figure 5-33: Saudi Arabia – Number of Diabetes Related Clinical Trials by Development Phase, 2020
Figure 5-34: Saudi Arabia – Number of Clinical Trials by Status, 2020
Figure 5-35: Saudi Arabia – Total Clinical Trials v/s CVS Related Clinical Trial 2020
Figure 5-36: Saudi Arabia – CVS Clinical Trial by Type of Disease, 2020
Figure 5-37: Saudi Arabia – CVS Clinical Trial by Disease Type (%), 2020
Figure 5-38: Saudi Arabia – Number of CVS Related Clinical Trials by Development Phase, 2020
Figure 5-39: Saudi Arabia – Number of CVS Related Clinical Trials by Development Phase, 2020
Figure 5-40: Saudi Arabia – Number of CVS Related Clinical Trials by Status, 2020
Figure 5-41: Saudi Arabia – Total Clinical Trials v/s Respiratory Diseases (Excluding Lung Cancer) Clinical Trials, 2020
Figure 5-42: Saudi Arabia – Number of Respiratory Diseases (Excluding Lung Cancer) Related Clinical Trials by Development Phase, 2020
Figure 5-43: Saudi Arabia – Number of Respiratory Diseases (Excluding Lung Cancer) Related Clinical Trials by Development Phase, 2020
Figure 5-44: Saudi Arabia – Number of Respiratory Diseases (Excluding Lung Cancer) Related Clinical Trials by Status, 2020
Figure 7-1: UAE – Number of Clinical Trials by Development Phase, 2020
Figure 7-2: UAE – Clinical Trials by Development Phase (%), 2020
Figure 7-3: UAE – Number of Clinical Trials by Status, 2020
Figure 7-4: UAE – Number of Drugs in Clinical Trials by Development Phase, 2020
Figure 7-5: UAE – Drugs in Clinical Trials by Development Phase (%), 2020
Figure 7-6: UAE – Number of Drugs in Clinical Trials by Top 20 Indication, 2020
Figure 7-7: UAE – Number of Drugs in Clinical Trials by Top 15 Drug Class, 2020
Figure 7-8: UAE – Number of Drugs in Clinical Trials by Mechanism of Action, 2020
Figure 7-9: UAE – Numbers of Clinical Trials by Indications, 2020
Figure 7-10: UAE – Clinical Trials by Indications (%), 2020
Figure 7-11: UAE – Number of Cancer Clinical Trials by Development Phase, 2020
Figure 7-12: UAE – Cancer Clinical Trials by Development Phase (%), 2020
Figure 7-13: UAE – Number of Cancer Clinical Trials by Status, 2020
Figure 7-14: UAE – Cancer Clinical Trials by Status (%), 2020
Figure 7-15: UAE – Number of Clinical Trials by Cancer Type, 2020
Figure 7-16: UAE – Clinical Trials by Cancer Type (%), 2020
Figure 7-17: UAE – Number of Breast Cancer Clinical Trials by Development Phase, 2020
Figure 7-18: UAE – Breast Cancer Clinical Trials by Developmental Stage (%), 2020
Figure 7-19: UAE – Number of Breast Cancer Clinical Trials by Status, 2020
Figure 7-20: UAE – Number of Breast Cancer Clinical Trials by Development Phase, 2020
Figure 7-21: UAE – Breast Cancer Clinical Trials by Developmental Stage (%), 2020
Figure 7-22: UAE – Number of Breast Cancer Clinical Trials by Status, 2020
Figure 7-23: UAE – Total Clinical Trials v/s Diabetes Clinical Trial 2020
Figure 7-24: UAE – Diabetes Clinical Trial by Type, 2020
Figure 7-25: UAE – Diabetes Clinical Trial by Type, 2020
Figure 7-26: UAE – Number of Diabetes Related Clinical Trials by Development Phase, 2020
Figure 7-27: UAE – Number of Diabetes Related Clinical Trials by Development Phase, 2020
Figure 7-28: UAE – Number of Clinical Trials by Status, 2020
Figure 7-29: UAE – Total Clinical Trials v/s CVS Related Clinical Trial 2020
Figure 7-30: UAE – CVS Clinical Trial by Type of Disease, 2020
Figure 7-31: UAE – CVS Clinical Trial by Disease Type (%), 2020
Figure 7-32: UAE – Number of CVS Related Clinical Trials by Development Phase, 2020
Figure 7-33: UAE – Number of CVS Related Clinical Trials by Development Phase, 2020
Figure 7-34: UAE – Number of CVS Related Clinical Trials by Status, 2020
Figure 9-1: Bahrain – Number of Clinical Trials by Development Phase, 2020
Figure 9-2: Bahrain – Clinical Trials by Development Phase (%), 2020
Figure 9-3: Bahrain – Number of Clinical Trials by Status, 2020
Figure 9-4: Bahrain – Number of Drugs in Clinical Trials by Development Phase, 2020
Figure 9-5: Bahrain – Drugs in Clinical Trials by Development Phase (%), 2020
Figure 9-6: Bahrain – Number of Drugs in Clinical Trials by Top 20 Indication, 2020
Figure 9-7: Bahrain – Number of Drugs in Clinical Trials by Top 15 Drug Class, 2020
Figure 9-8: Bahrain – Number of Drugs in Clinical Trials by Mechanism of Action, 2020
Figure 9-9: Bahrain – Numbers of Clinical Trials by Indications, 2020
Figure 9-10: Bahrain – Clinical Trials by Indications (%), 2020
Figure 9-11: Bahrain – Number of COVID 19 Clinical Trials by Development Phase, 2020
Figure 9-12: Bahrain – COVID 19 Clinical Trials by Development Phase (%), 2020
Figure 9-13: Bahrain – Number of Clinical Trials by Status, 2020
Figure 11-1: Oman – Number of Clinical Trials by Development Phase, 2020
Figure 11-2: Oman – Clinical Trials by Development Phase (%), 2020
Figure 11-3: Oman – Number of Clinical Trials by Status, 2020
Figure 11-4: Oman – Number of Drugs in Clinical Trials by Development Phase, 2020
Figure 11-5: Oman – Drugs in Clinical Trials by Development Phase (%), 2020
Figure 11-6: Oman – Number of Drugs in Clinical Trials by Top 20 Indication, 2020
Figure 11-7: Oman – Number of Drugs in Clinical Trials by Top 15 Drug Class, 2020
Figure 11-8: Oman – Number of Drugs in Clinical Trials by Mechanism of Action, 2020
Figure 11-9: Oman – Numbers of Clinical Trials by Indications, 2020
Figure 11-10: Oman – Clinical Trials by Indications (%), 2020
Figure 11-11: Oman – Number of Sickle Cell Disease Clinical Trials by Development Phase, 2020
Figure 11-12: Oman – Sickle Cell Disease Clinical Trials by Development Phase (%), 2020
Figure 11-13: Oman – Number of Sickle Cell Disease Clinical Trials by Status, 2020
Figure 11-14: Oman – Number of Cancer Clinical Trials by Status, 2020
Figure 11-15: Oman – Cancer Clinical Trials by Status (%), 2020
Figure 11-16: Oman – Number of Clinical Trials by Type of Cancer, 2020
Figure 11-17: Oman – Clinical Trials by Type of Cancer (%), 2020
Figure 13-1: Kuwait – Number of Clinical Trials by Development Phase, 2020
Figure 13-2: Kuwait – Clinical Trials by Development Phase (%), 2020
Figure 13-3: Kuwait – Number of Clinical Trials by Status, 2020
Figure 13-4: Kuwait – Number of Drugs in Clinical Trials by Development Phase, 2020
Figure 13-5: Kuwait – Drugs in Clinical Trials by Development Phase (%), 2020
Figure 13-6: Kuwait – Number of Drugs in Clinical Trials by Top 20 Indication, 2020
Figure 13-7: Kuwait – Number of Drugs in Clinical Trials by Top 15 Drug Class, 2020
Figure 13-8: Kuwait – Number of Drugs in Clinical Trials by Mechanism of Action, 2020
Figure 13-9: Kuwait – Numbers of Clinical Trials by Indications, 2020
Figure 13-10: Kuwait – Clinical Trials by Indications (%), 2020
Figure 13-11: Kuwait – Number of Cancer Clinical Trials by Development Phase, 2020
Figure 13-12: Kuwait – Cancer Clinical Trials by Development Phase (%), 2020
Figure 13-13: Kuwait – Number of Cancer Clinical Trials by Status, 2020
Figure 13-14: Kuwait – Number of Clinical Trials by Type of Cancer, 2020
Figure 13-15: Kuwait – Total Clinical Trials v/s Diabetes Clinical Trial 2020
Figure 13-16: Kuwait – Diabetes Clinical Trial by Type, 2020
Figure 13-17: Kuwait – Diabetes Clinical Trial by Type, 2020
Figure 13-18: Kuwait – Number of Diabetes Related Clinical Trials by Development Phase, 2020
Figure 13-19: Kuwait – Number of Diabetes Related Clinical Trials by Development Phase, 2020
Figure 13-20: Kuwait – Number of Clinical Trials by Status, 2020
Figure 14-1: Qatar – Number of Clinical Trials by Development Phase, 2020
Figure 14-2: Qatar – Clinical Trials by Development Phase (%), 2020
Figure 14-3: Qatar – Number of Clinical Trials by Status, 2020
Figure 14-4: Qatar – Number of Drugs in Clinical Trials by Development Phase, 2020
Figure 14-5: Qatar – Drugs in Clinical Trials by Development Phase (%), 2020
Figure 14-6: Qatar – Number of Drugs in Clinical Trials by Top 20 Indication, 2020
Figure 14-7: Qatar – Number of Drugs in Clinical Trials by Top 15 Drug Class, 2020
Figure 14-8: Qatar – Number of Drugs in Clinical Trials by Top Mechanism of Action, 2020
Figure 14-9: Qatar – Numbers of Clinical Trials by Indications, 2020
Figure 14-10: Qatar – Clinical Trials by Indications (%), 2020
Figure 14-11: Qatar – Number of Cancer Clinical Trials by Development Phase, 2020
Figure 14-12: Qatar – Cancer Clinical Trials by Development Phase (%), 2020
Figure 14-13: Qatar – Number of Cancer Clinical Trials by Status, 2020
Figure 14-14: Qatar – Number of Clinical Trials by Type of Cancer, 2020
Figure 14-15: Qatar – Total Clinical Trials v/s Diabetes Clinical Trial 2020
Figure 14-16: Qatar – Diabetes Clinical Trial by Type, 2020
Figure 14-17: Qatar – Diabetes Clinical Trial by Type, 2020
Figure 14-18: Qatar – Number of Diabetes Related Clinical Trials by Development Phase, 2020
Figure 14-19: Qatar – Number of Diabetes Related Clinical Trials by Development Phase, 2020
Figure 14-20: Qatar – Number of Clinical Trials by Status, 2020
Figure 14-21: Qatar – Total Clinical Trials v/s CVS Related Clinical Trial 2020
Figure 14-22: Qatar – CVS Clinical Trial by Type of Disease, 2020
Figure 14-23: Qatar – Number of CVS Related Clinical Trials by Development Phase, 2020
Figure 14-24: Qatar – Number of CVS Related Clinical Trials by Development Phase, 2020
Figure 14-25: Qatar – Number of CVS Related Clinical Trials by Status, 2020
Figure 14-26: Qatar – Total Clinical Trials v/s Respiratory Disease (Except Lung Cancer) Related Clinical Trial 2020
Figure 14-27: Qatar – Number of Respiratory Diseases (Excluding Lung Cancer) Related Clinical Trials by Development Phase, 2020
Figure 14-28: Qatar – Number of Respiratory Diseases (Excluding Lung Cancer) Related Clinical Trials by Development Phase, 2020
Figure 14-29: Qatar – Number of Respiratory Diseases (Excluding Lung Cancer) Related Clinical Trials by Status, 2020
